Business
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conferenc...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\nOncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY and SAN DIEGO, Sept. 19, 2017\n\n\n\nDr. Andres Gutierrez, Oncolytics' Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an immuno-oncology viral agent to treat cancer\n\n\n\nCALGARY and SAN DIEGO, Sept. 19, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced that it will present at the Phacilitate Immuno-Oncology Frontiers Conference.  Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, will present at 4:00 pm CEST on September 21, 2017 at the Maritim Proarte Hotel. The conference takes place on September 20th and 21st in Berlin, Germany.\n\nDr. Gutierrez will highlight the role of REOLYSIN in the activation of the immune system and the induction of an inflamed tumor phenotype in the tumor microenvironment.  His presentation will also review certain historical clinical programs, highlight the positive survival data from the IND 213 study in metastatic breast cancer (mBC) and the pooled safety database – the largest of any oncolytic virus. \n\n\"We want to share our extensive experience with REOLYSIN in the clinic to illustrate the specific expertise and efforts required to develop an oncolytic virus for intravenous administration and systemic exposure in oncology,\" said Dr. Gutierrez. \"This experience helped us define a clear regulatory pathway for registration in metastatic breast cancer. With an overall agreement with the FDA on the phase 3 study design, details of the pivotal registration study will be made available following evaluation and completion of discussions with clinical advisors and potentially partners, as well as European regulators.\"\n\nThe Phaci...